Literature DB >> 26328203

Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy.

Sıtkı Ün1, Hakan Türk1, Osman Koca1, Rauf Taner Divrik1, Ferruh Zorlu1.   

Abstract

OBJECTIVE: This study was conducted to research the factors determining biochemical recurrence (BCR) in low-risk localized prostate cancer patients who underwent radical prostatectomy (RP).
MATERIALS AND METHODS: We retrospectively analyzed the data of 504 patients who had undergone RP between 2003 and 2013 at our clinic. One hundred and fifty-two patients who underwent RP for low-risk prostate cancer were included in the study.
RESULTS: The mean follow-up period for patients was 58.7 (21-229) months. The mean age of the patients was 63.7±7.2 years (49-79). The mean prostate specific antigen (PSA) value was 5.25±4.22 ng/mL (3.58-9.45). The BCR rate after the operation was 25% (38/152). In the univariate analysis, recurrence determining factors were shown to include extracapsular involvement (ECI) (p=0.004), capsular invasion (CI) (p=0.001), age (p=0.014), and tumor size (p=0.006). However, only CI was found to be significant in multivariate analysis (p=0.001).
CONCLUSION: Capsular invasion is an independent risk factor in low-risk prostate cancer patients who underwent RP for BCR.

Entities:  

Keywords:  Biochemical recurrence; low-risk; radical prostatectomy

Year:  2015        PMID: 26328203      PMCID: PMC4548661          DOI: 10.5152/tud.2015.65624

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  51 in total

Review 1.  Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.

Authors:  D G Bostwick; D J Grignon; M E Hammond; M B Amin; M Cohen; D Crawford; M Gospadarowicz; R S Kaplan; D S Miller; R Montironi; T F Pajak; A Pollack; J R Srigley; J W Yarbro
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

2.  Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage.

Authors:  Lars Budäus; Hendrik Isbarn; Christian Eichelberg; Giovanni Lughezzani; Maxine Sun; Paul Perrotte; Felix K H Chun; Georg Salomon; Thomas Steuber; Jens Köllermann; Guido Sauter; Sascha A Ahyai; Mario Zacharias; Margit Fisch; Thorsten Schlomm; Alexander Haese; Hans Heinzer; Hartwig Huland; Francesco Montorsi; Markus Graefen; Pierre I Karakiewicz
Journal:  J Urol       Date:  2010-08-17       Impact factor: 7.450

3.  Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of medicare-age men.

Authors:  Michael J Barry; Patricia M Gallagher; Jonathan S Skinner; Floyd J Fowler
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

4.  Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.

Authors:  Stephen J Freedland; George S Csathy; Frederick Dorey; William J Aronson
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

5.  Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.

Authors:  Anthony V D'Amico; Richard Whittington; S Bruce Malkowicz; Kerri Cote; Marian Loffredo; Delray Schultz; Ming-Hui Chen; John E Tomaszewski; Andrew A Renshaw; Alan Wein; Jerome P Richie
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

6.  Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening.

Authors:  Michael Aleman; Pierre I Karakiewicz; Patrick Kupelian; Michael W Kattan; Markus Graefen; Ilias Cagiannos; James Eastham; Peter T Scardino; Hartwig Huland; Eric A Klein
Journal:  Urology       Date:  2003-07       Impact factor: 2.649

7.  Prediction of perineural invasion and its prognostic value in patients with prostate cancer.

Authors:  Jun Taik Lee; Seungsoo Lee; Chang Jin Yun; Byung Joo Jeon; Jung Man Kim; Hong Koo Ha; Wan Lee; Moon Kee Chung
Journal:  Korean J Urol       Date:  2010-11-17

8.  Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression.

Authors:  Laurent Salomon; Aristotelis G Anastasiadis; Christopher W Johnson; James M McKiernan; Erik T Goluboff; Claude C Abbou; Carl A Olsson; Mitchell C Benson
Journal:  Urology       Date:  2003-08       Impact factor: 2.649

9.  The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.

Authors:  John F Ward; Michael L Blute; Jeffrey Slezak; Erik J Bergstralh; Horst Zincke
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

10.  Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors.

Authors:  Laurent Salomon; Olivier Levrel; Aristotelis G Anastasiadis; Jacques Irani; Alexandre De La Taille; Fabien Saint; Dimitri Vordos; Antony Cicco; Andras Hoznek; Dominique Chopin; Claude Clément Abbou
Journal:  Eur Urol       Date:  2003-01       Impact factor: 20.096

View more
  3 in total

1.  Prognostic significance of a novel indicator (PSApostd3/PSApre) for PSA recurrence in patients after radical prostatectomy.

Authors:  Zhien Zhou; Yinyan Xu; Qianyue Li; Weigang Yan; Yi Zhou; Zhibo Zheng; Hanzhong Li; Zhigang Ji
Journal:  Cancer Manag Res       Date:  2019-06-25       Impact factor: 3.989

2.  Analysis of outcomes after non-contour-based dose painting of dominant intra-epithelial lesion in intra-operative low-dose rate brachytherapy.

Authors:  Kevin Martell; Soumyajit Roy; Tyler Meyer; Jordan Stosky; Will Jiang; Kundan Thind; Michael Roumeliotis; John Bosch; Steve Angyalfi; Harvey Quon; Siraj Husain
Journal:  Heliyon       Date:  2020-06-07

Review 3.  Proton therapy- the modality of choice for future radiation therapy management of Prostate Cancer?

Authors:  Sophie Mangan; Michelle Leech
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2019-10-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.